Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Multicenter, Double-Blind, Randomized, Comparative Study to Estimate the Safety, Tolerability and Efficacy of NXL104/Ceftazidime Plus Metronidazole vs. Meropenem in the Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults.

Next Previous
Search
Trial Profile

A Prospective, Multicenter, Double-Blind, Randomized, Comparative Study to Estimate the Safety, Tolerability and Efficacy of NXL104/Ceftazidime Plus Metronidazole vs. Meropenem in the Treatment of Complicated Intra-Abdominal Infections in Hospitalized Adults.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avibactam/ceftazidime (Primary) ; Meropenem; Metronidazole
  • Indications Bacterial infections; Intra-abdominal infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novexel; Pfizer

    • Most Recent Events

    • 29 Jun 2020 Results evaluating the safety of ceftazidime-avibactam in adults published in the Drug Safety
    • 05 Jun 2017 Primary endpoint of clinical response at the TOC visit in microbiologically evaluable has not been met, according to results presented at the ASM Microbe 2017.
    • 05 Jun 2017 Results presented at the ASM Microbe 2017

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top